<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kindler epidermolysis bullosa</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kindler epidermolysis bullosa</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kindler epidermolysis bullosa</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cristina Has, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H131800537"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kindler epidermolysis bullosa (KEB; MIM #173650), or Kindler syndrome, is a rare autosomal recessive type of epidermolysis bullosa characterized by skin blistering, photosensitivity, progressive poikiloderma (the combination of extensive skin atrophy, telangiectasias, and pigmentary changes), and squamous cell carcinomas of skin and mucosal membranes. It was first described in 1954 by Theresa Kindler and considered a poikilodermatous disorder until 2008, when it was classified as a distinct type of epidermolysis bullosa [<a href="#rid1">1,2</a>]. As the first genetic cutaneous disorder associated with alterations in proteins of focal adhesions (intracellular attachment points to extracellular matrix) [<a href="#rid3">3</a>], KEB and its pathogenesis became an important model for understanding the role of focal adhesions in the skin.</p><p>This topic will discuss the pathogenesis, clinical features, diagnosis, and management of KEB. Other types of inherited epidermolysis bullosa are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa"</a>.)</p><p></p><p class="headingAnchor" id="H131800543"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence and prevalence of KEB are unknown. The disease occurs worldwide and affects males and females of all ethnic groups. More than 250 cases have been reported in the literature so far (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatabases.lovd.nl%2Fshared%2Fgenes&amp;token=hwlBMygTvebQR3qzrrjEJ7Gw18NruPiosuiiYFCT0Sa6hWK8nmbwqlauu7j12hrg&amp;TOPIC_ID=15510" target="_blank">Leiden Open Variation Database [LOVD]</a>) [<a href="#rid4">4</a>]. Like all autosomal recessive conditions, it is more prevalent in populations with a high degree of consanguineous marriages and in isolates, such as Iran or Panama [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H131800549"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H71742176"><span class="h2">Kindlin-1 protein</span><span class="headingEndMark"> — </span>KEB is caused by variants in the <em>FERMT1 </em>gene,<em> </em>encoding FFH1 (also referred to as kindlin-1), a focal adhesion protein predominantly expressed in skin basal keratinocytes, periodontal tissues, and the colon [<a href="#rid7">7,8</a>]. Kindlin-1 is an intracellular adaptor protein of the integrin-linked adhesion sites, known as focal adhesions in cell cultures  (<a class="graphic graphic_figure graphicRef103177" href="/d/graphic/103177.html" rel="external">figure 1</a>). Functionally, focal adhesions represent supramolecular signaling and actin-anchoring platforms.</p><p>In human adult tissues, kindlin-1 is expressed in tissues of ectodermal and endodermal origin, in particular in the skin, periodontal tissues, intestinal epithelium, and kidneys [<a href="#rid7">7,9,10</a>]. In the skin and oral mucosa, kindlin-1 is localized in basal epidermal keratinocytes in a polarized manner facing the basement membrane [<a href="#rid11">11</a>]. In the colon and rectum, kindlin-1 is localized to the plasma membrane of the epithelial cells, colocalized with ezrin and beta-catenin [<a href="#rid12">12</a>]. Together with talin, kindlins directly bind the beta-subunit cytoplasmic tails of integrins and are responsible for integrin activation and trafficking [<a href="#rid13">13-15</a>].</p><p>In KEB, skin-disorganized keratinocytes lose their proper architecture, polarization, and adhesion to the dermis [<a href="#rid11">11</a>]. In vitro, loss of kindlin-1 is associated with abnormal cell shape, modification of the cortical actin network, and increased plasticity of the plasma membrane; functionally, cell adhesion, spreading, and directed motility are perturbed [<a href="#rid11">11,14,16</a>]. In immortalized human keratinocytes, kindlin-1 was necessary for mediating epidermal growth factor (EGF)-induced activation signals, including integrin beta-1 activation, focal adhesion kinase (FAK) phosphorylation, and actin reorganization, which resulted in enhanced cell proliferation and migration [<a href="#rid17">17</a>]. These results indicate that kindlin-1 is essential in EGF-induced re-epithelialization in skin wound healing. In KEB keratinocytes, kindlin-1 has been shown to regulate the expression, subcellular distribution, and degradation of epidermal growth factor receptor (EGFR) [<a href="#rid18">18</a>].</p><p>KEB-affected cells in culture display minimal proliferation of basal keratinocytes and strongly impaired survival of keratinocytes, which explain the characteristic epidermal atrophy in KEB patients [<a href="#rid11">11</a>]. The underlying mechanisms include involvement of kindlin-1 in mitotic spindle formation and control of stem cell proliferation [<a href="#rid19">19,20</a>].</p><p>Several studies have shed some light on the molecular mechanisms underlying photosensitivity in KEB: </p><p class="bulletIndent1"><span class="glyph">●</span>In a mouse model study, <em>FERMT1</em> knockdown impaired DNA repair, as indicated by the increased detection of gamma-H2AX and cyclobutane pyrimidine dimers 24 hours after ultraviolet B (UVB) radiation [<a href="#rid21">21</a>]. Kindlin-1 deficiency sensitized keratinocytes to cytokine and ultraviolet (UV)-induced nuclear factor (NF)-kappa-B and c-Jun N-terminal kinase activation, while genetic or pharmacologic c-Jun N-terminal kinase inhibition and NF-kappa-B inhibition markedly reduced cyclobutane pyrimidine dimers-positive cells [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proinflammatory cytokines interleukin (IL) 1-beta, IL-6, and tumor necrosis factor (TNF)-alpha are upregulated in KEB skin and in UVB-irradiated KEB keratinocytes [<a href="#rid22">22</a>]. Expression of these cytokines depends on p38 activation, which is increased in the absence of kindlin-1 and by increased levels of reactive oxygen species. Low levels of kindlin-1 are sufficient to rescue this feature, while overexpression of kindlin-2 has no compensatory effect [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kindlin-1 is required to fully activate extracellular signal-regulated kinase (ERK) signaling after oxidative damage, and ERK activation protects cells from DNA damage following oxidative stress [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keratinocytes from KEB patients have significantly reduced expression levels of the EGFR, resulting in defective EGF-dependent signaling. Kindlin-1 can associate directly with EGFR in vitro in an EGF-dependent, integrin-independent manner, and formation of this complex is required for EGF-dependent migration. Moreover, kindlin-1 acts to protect EGFR from lysosomal-mediated degradation [<a href="#rid18">18</a>].</p><p></p><p>The pathogenesis of dermal fibrosis resulting from lack of kindlin-1 has been clarified, at least in part. Kindlin-1-deficient keratinocytes respond to cell stress (eg, UV irradiation) by upregulating the expression of proinflammatory and profibrotic cytokines such as IL-20, IL-24, transforming growth factor (TGF)-beta-2, platelet-derived growth factor-beta (PDGFB), connective tissue growth factor (CTGF), and matrix metalloproteinases [<a href="#rid16">16,25</a>]. These cytokines initiate an inflammatory response in the dermis, resulting in the activation of fibroblasts and their differentiation to myofibroblasts, which secrete and deposit increased amounts of extracellular matrix proteins [<a href="#rid25">25</a>]. Repeated cycles of epidermal cell stress, cytokine secretion, dermal inflammation, and profibrotic processes underlie the mucocutaneous fibrosis in KEB [<a href="#rid25">25</a>]. RNA sequencing (RNA-seq) of fibroblasts from KEB patients demonstrates derangement of the extracellular matrix via transforming growth factor-beta signaling activation and oxidative state imbalance [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H131800555"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>KEB is inherited in an autosomal recessive manner. <em>FERMT1</em> pathogenic variants are found in patients in a homozygous or compound heterozygous state. The molecular pathology is complex, and in addition to a few recurrent variants (eg, c.676dup), many families bear their "private" mutations [<a href="#rid26">26</a>]. <em>FERMT1</em> variants are distributed over the entire gene, spanning exons, introns, and the promoter region. The variant types include nonsense variants, small deletions, and insertions leading to frameshift and premature termination codons and absence of the protein. Splice-site variants may have the same outcome or allow the expression of truncated polypeptides [<a href="#rid27">27</a>]. In addition, large deletions, promoter variants, and deep intronic variants have been described [<a href="#rid6">6,28-30</a>].</p><p class="headingAnchor" id="H131800561"><span class="h1">CLINICAL MANIFESTATIONS AND NATURAL HISTORY</span><span class="headingEndMark"> — </span>The main clinical features of KEB are skin blistering, photosensitivity, extensive skin atrophy, poikiloderma (the combination of skin atrophy, telangiectasias, and pigmentary changes), and sclerotic features. The phenotype is progressive during the patient's life. In adults, the main cutaneous findings are poikiloderma and mucocutaneous scarring, leading to stenoses of the esophagus and genitourinary tract, ectropion, and webbing of fingers.</p><p class="headingAnchor" id="H131800567"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>Skin blistering is usually present at birth and shows an acral distribution  (<a class="graphic graphic_picture graphicRef103491" href="/d/graphic/103491.html" rel="external">picture 1</a>). It persists during childhood, but the tendency to develop blisters decreases with age. Blisters have no characteristic features to allow the distinction from other types of epidermolysis bullosa. Initially, they heal without scarring, but skin atrophy and sclerosis develop over time.</p><p>The severity of photosensitivity is variable and seems to be independent of the skin phototype [<a href="#rid31">31</a>]. Most patients experience mild or unnoticeable photosensitivity.</p><p>Skin atrophy beginning on the dorsal aspects of the hands and feet is recognizable as early as at the age of one to two years  (<a class="graphic graphic_picture graphicRef103492" href="/d/graphic/103492.html" rel="external">picture 2</a>) and is a valuable clue for the diagnosis of KEB. Skin atrophy extends progressively to the entire integument. Poikiloderma can be first recognized around the age of 10 years, first localized to sun-exposed areas and later disseminated on the entire body surface  (<a class="graphic graphic_picture graphicRef103494" href="/d/graphic/103494.html" rel="external">picture 3</a>).</p><p>Many adults with KEB have dry skin and develop diffuse keratoses of hands and feet. On this background, dermatophyte infections such as tinea pedis are common. Sclerotic features of the hands and feet such as webbing, sclerodermiform appearance of fingers, or pseudoainhum (constrictions of the fingers)  (<a class="graphic graphic_picture graphicRef103496" href="/d/graphic/103496.html" rel="external">picture 5B</a>) manifest in young adults with significant variability, probably related to the extent of exposure to environmental factors.</p><p>Loss of dermatoglyphics mirrors skin atrophy  (<a class="graphic graphic_picture graphicRef103497" href="/d/graphic/103497.html" rel="external">picture 4</a>); patients should be aware of this feature.</p><p class="headingAnchor" id="H131800573"><span class="h2">Hair and nail changes</span><span class="headingEndMark"> — </span>Scalp hair is not changed, but adults with KEB have sparse body hair. Nail dystrophy is common and may accompany the sclerosis of the fingers and pseudoainhum  (<a class="graphic graphic_picture graphicRef103498 graphicRef103496" href="/d/graphic/103498.html" rel="external">picture 5A-B</a>). Onychomycosis may also be associated.</p><p class="headingAnchor" id="H131800585"><span class="h2">Mucosal lesions</span><span class="headingEndMark"> — </span>Mucosal fragility is very common in patients with KEB [<a href="#rid32">32</a>]. The oral mucosa is most frequently affected, with mechanically induced bleeding and erosions and early and severe periodontitis that may lead to premature loss of teeth  (<a class="graphic graphic_picture graphicRef103568" href="/d/graphic/103568.html" rel="external">picture 6</a>) [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/d/html/6281.html" rel="external">"Periodontal disease in children: Associated systemic conditions", section on 'Kindler epidermolysis bullosa'</a>.)</p><p>Most young adults with KEB suffer from progressive dysphagia and esophageal strictures requiring repeated dilatations. Intestinal involvement (ie, colitis induced by epitheliolysis) has been reported in a few cases [<a href="#rid12">12,35,36</a>].</p><p>Anal, urogenital, and ocular mucosa involvement is also common [<a href="#rid35">35</a>]. Urethral stenosis can occur in male patients during childhood or later in life [<a href="#rid32">32,37,38</a>]. Vaginal stenosis and effacement of the external female genitals have been reported in female patients [<a href="#rid37">37,39</a>].</p><p>Patients with ocular involvement may develop ectropion and recurrent keratoconjunctivitis resulting in symblepharon [<a href="#rid32">32,40</a>].</p><p class="headingAnchor" id="H131800591"><span class="h2">Mucocutaneous malignancies</span><span class="headingEndMark"> — </span>Patients with KEB have an increased risk of developing mucocutaneous squamous cell carcinomas. In a cohort of 91 patients with KEB, the youngest patient with squamous cell carcinoma was a 29-year-old patient [<a href="#rid41">41</a>]. The risk of squamous cell carcinoma increased with age up to 67 percent in patients over 60 years of age. The most frequently involved sites were the extremities, lips, and oral mucosa. Fifty-four percent of patients with squamous cell carcinoma developed metastatic disease. Despite a well-differentiated histopathology, these tumors have an aggressive behavior, with a tendency to recur and metastasize [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H131800597"><span class="h2">Revertant mosaicism</span><span class="headingEndMark"> — </span>Patients with KEB due to specific <em>FERMT1</em> variants demonstrate a particular, disseminated pattern of revertant mosaicism  (<a class="graphic graphic_picture graphicRef103618" href="/d/graphic/103618.html" rel="external">picture 7</a>) [<a href="#rid43">43,44</a>]. Revertant mosaicism, also called "spontaneous gene repair" or "natural gene therapy," has been documented in several genetic disorders involving organs that undergo self-regeneration, including the skin and in all types of epidermolysis bullosa [<a href="#rid45">45</a>]. In patients with KEB, revertant patches can be recognized as soon as the affected skin becomes atrophic. Revertant areas are stable in time and preserve a normal skin texture, in contrast to the surrounding atrophic skin  (<a class="graphic graphic_picture graphicRef103618" href="/d/graphic/103618.html" rel="external">picture 7</a>).</p><p class="headingAnchor" id="H131800603"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Histopathology of KEB skin shows epidermal atrophy and hyperkeratosis, microblisters at the dermal-epidermal junction, presence of sunburn cells, and pigment incontinence. In the dermis, there are dilated vessels and fragmented and sparse elastic fibers  (<a class="graphic graphic_picture graphicRef103619" href="/d/graphic/103619.html" rel="external">picture 8</a>).</p><p class="headingAnchor" id="H131800609"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H71742370"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>In neonates, the diagnosis of KEB cannot be suspected clinically, since blistering cannot be distinguished from other types of epidermolysis bullosa [<a href="#rid1">1</a>]. In older children, the coexistence of skin blistering, photosensitivity, and cigarette-paper-like atrophy on the dorsal aspects of the hands raise the suspicion of KEB. In adults, poikiloderma in conjunction with a history of blistering and photosensitivity during childhood suggests the diagnosis.</p><p class="headingAnchor" id="H131800635"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A 4 mm punch biopsy taken from a freshly induced blister can be performed for the diagnosis [<a href="#rid46">46</a>]. The technique for obtaining and processing an optimal specimen for immunofluorescence microscopy and/or transmission electron microscopy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa", section on 'Obtaining biopsies for epidermolysis bullosa diagnosis'</a>.)</p><p class="headingAnchor" id="H156820277"><span class="h3">Transmission electron microscopy</span><span class="headingEndMark"> — </span>In KEB, the level of skin cleavage is variable, intraepidermal and subepidermal, and can be discriminated by transmission electron microscopy. This technique demonstrates splits within the basal keratinocytes, in the lamina lucida and/or below the lamina densa, as well as reduplications and branches of the lamina densa of the basement membrane [<a href="#rid1">1</a>]. However, transmission electron microscopy is not widely accessible, and interpretation requires special expertise.</p><p class="headingAnchor" id="H156820283"><span class="h3">Immunofluorescence antigen mapping</span><span class="headingEndMark"> — </span>Immunofluorescence staining with antibodies to components of the dermal-epidermal junction zone (eg, bullous pemphigoid-1 antigen, laminin-332, collagen IV, keratin 14) may be employed alternatively as a first diagnostic step in patients with suspected KEB. This procedure, also known as antigen mapping or immunofluorescence mapping, is widely used for the diagnostics of other types of epidermolysis bullosa [<a href="#rid47">47-49</a>]. (See  <a class="medical medical_review" href="/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa", section on 'Immunofluorescence mapping'</a>.)</p><p>In KEB skin, microblisters at the dermal-epidermal junction are indicated by discontinuous staining of markers such as type IV collagen or laminin-332. An irregular, broad staining pattern of laminin-332 and type VII collagen is highly suggestive of the diagnosis  (<a class="graphic graphic_picture graphicRef103627" href="/d/graphic/103627.html" rel="external">picture 9</a>) [<a href="#rid50">50</a>].</p><p>A negative staining with antibodies to kindlin-1 would specifically indicate the absence of this protein in the patient's skin. However, the available antibodies are not suitable for diagnosis, due to a high background staining with only a faint specific signal.</p><p class="headingAnchor" id="H131800641"><span class="h2">Mutation analysis</span><span class="headingEndMark"> — </span>Mutation analysis represents the gold standard for the diagnosis of KEB. More than 70 distinct <em>FERMT1</em> variants have been reported (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.hgmd.cf.ac.uk%2Fac%2Findex.php&amp;token=w7p0LC3%2F%2Bc5TTfDIkVSPKuXOHlNonGDNq2foBOcxWHjS2ipCxB5EMN1sOeOrxH2h&amp;TOPIC_ID=15510" target="_blank">Human Gene Mutation Database [HGMD]</a>; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdatabases.lovd.nl%2Fshared%2Fgenes&amp;token=hwlBMygTvebQR3qzrrjEJ7Gw18NruPiosuiiYFCT0Sa6hWK8nmbwqlauu7j12hrg&amp;TOPIC_ID=15510" target="_blank">Leiden Open Variation Database [LOVD]</a>). Mutation analysis may be performed as candidate gene testing or by using targeted gene panel or whole exome next-generation sequencing (NGS)-based analyses [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications"</a>.)</p><p>Because of the diverse mutational mechanisms, additional tests, such as quantitative real-time polymerase chain reaction (PCR), multiplex ligation-dependent probe amplification (MLPA), or RNA sequencing, may be required to disclose mutations. Whole-exome sequencing may also be employed, but will not capture particular types of mutations for which whole-genome sequencing or RNA sequencing are required. Genetically unsolved cases may be due to particular mutations in regions of <em>FERMT1</em> that are not covered by routine diagnostic procedures [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H131800653"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In children and adults, the differential diagnosis of KEB includes other types of epidermolysis bullosa and poikilodermatous and sclerotic disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dystrophic epidermolysis bullosa</strong> – In many patients with KEB, the diagnosis of dystrophic epidermolysis bullosa is first considered, based upon the presence of blistering, scarring, esophageal stenosis, and abnormal staining of collagen type VII in the skin. The clinical assessment of skin atrophy, photosensitivity, poikiloderma, and gingivitis may help to distinguish the two disorders. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Dystrophic epidermolysis bullosa'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Junctional epidermolysis bullosa</strong> – A distinct subtype of late-onset junctional epidermolysis bullosa caused by specific variants in the gene for collagen XVII may present with clinical features that resemble KEB, in particular mild blistering, progressive skin atrophy, and irregular deposition of markers of the dermal-epidermal junction zone [<a href="#rid51">51</a>]. Features that support the diagnosis of junctional epidermolysis bullosa include nail loss, lack of photosensitivity, and the demonstration of the amino-acid substitution p.R1303Q in collagen XVII [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Junctional epidermolysis bullosa'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermolysis bullosa simplex</strong> – Patients with KEB are sometimes initially diagnosed with epidermolysis bullosa simplex, which shares some clinical features with KEB, such as mild acral blistering that improves with age. The identification of additional clinical and molecular characteristics of KEB allows the correct diagnosis. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Epidermolysis bullosa simplex'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyskeratosis congenita</strong> – Dyskeratosis congenita is an inherited bone marrow failure syndrome associated with poikiloderma, palmoplantar hyperkeratosis, mucosal involvement, and predisposition to cancer  (<a class="graphic graphic_picture graphicRef76566" href="/d/graphic/76566.html" rel="external">picture 10</a> and <a class="graphic graphic_table graphicRef81497" href="/d/graphic/81497.html" rel="external">table 1</a>). Detailed history, careful clinical assessment, and laboratory work-up allow the discrimination of the two entities. (See  <a class="medical medical_review" href="/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rothmund-Thomson syndrome</strong> – Rothmund-Thomson syndrome is characterized by poikiloderma; sparse hair, eyelashes, and/or eyebrows; small stature; skeletal and dental abnormalities; cataracts; and an increased risk for cancer, especially osteosarcoma [<a href="#rid52">52</a>]. Detailed history and careful clinical assessment allow the discrimination of the two entities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poikiloderma with neutropenia, Clericuzio type</strong> – Poikiloderma with neutropenia, Clericuzio type (MIM #604173) is a rare autosomal recessive genodermatosis characterized by poikiloderma, chronic neutropenia, recurrent pulmonary infections, short stature, facial dysmorphism, pachyonychia, palmoplantar keratoderma, and skeletal defects [<a href="#rid53">53-56</a>]. The disease, initially described in the Navajo population, is caused by variants in the <em>C16orf57</em> gene on 16q13 [<a href="#rid55">55,57</a>]. Patients present with a papular erythematous rash on the limbs during the first year of life that results in progressive poikiloderma. KEB may be initially suspected in patients with poikiloderma with neutropenia, but lack of blistering and the presence of neutropenia should discriminate these two entities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP)</strong> – POIKTMP (MIM #615704) is characterized by poikiloderma, hypohidrosis, lymphedema of the extremities, sclerosis of the digits, mild palmoplantar keratoderma, sparse hair, and nail dystrophy. Extracutaneous features include progressive weakness of the proximal and distal muscles of the limbs, interstitial pulmonary fibrosis, exocrine pancreatic insufficiency, liver and hematologic abnormalities, short stature, and cataract. POIKTMP is caused by variants of <em>FAM111B</em> and is inherited in an autosomal dominant manner [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic sclerosis</strong> – Mild phenotypes in adults with KEB may be misdiagnosed as systemic sclerosis, based upon the presence of mucocutaneous findings such as sclerotic fingers, microstomia, and esophageal stenosis [<a href="#rid37">37,58</a>]. Detailed history, careful clinical examination, and the demonstration of a <em>FERMT1</em> variant lead to the correct diagnosis. (See  <a class="medical medical_review" href="/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H131800659"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no specific treatment for KEB. There are no experimental targeted therapies such as gene, cell, or protein therapy envisioned so far to replace kindlin-1. Genotype-phenotype correlation studies suggest that increasing the expression of kindlin-1 by approximately 10 percent would significantly alleviate the phenotype [<a href="#rid23">23</a>]. Experimental evidence for potential benefit from antioxidant therapies needs to be translated into clinical trials [<a href="#rid22">22,24</a>].</p><p>The management is largely supportive and involves an interdisciplinary team for the treatment of the complications that occur progressively, such as limited mobility of fingers, esophageal and urethral stenoses, conjunctivitis, and severe periodontitis. (See  <a class="medical medical_review" href="/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa"</a>.)</p><p>The management strategy involves the following:</p><p class="bulletIndent1"><span class="glyph">●</span>General skin care measures, including avoidance of mechanical trauma and frequent use of moisturizers; for blisters and erosions, antiseptics and nonadhesive wound dressings should be employed [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be educated to adopt photoprotection measures, even if they do not manifest photosensitivity. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Careful and regular dental care is mandatory to prevent the development of periodontitis [<a href="#rid60">60</a>]. Mechanical pressure and irritations of the oral mucosa should be avoided, since they may contribute to inflammation and carcinogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eye care and regular ophthalmologic evaluation is an important part of the management of patients with KEB, particularly for patients who develop ectropion [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal and urethral stenosis may require repeated dilatations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caloric supplementation and fluid diet should be considered if body mass index is reduced due to difficulties in eating and swallowing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hand surgery may be required for pseudoainhum and pseudosyndactyly. Revertant skin patches can be used for grafting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should undergo regular total-body skin examinations for early detection of skin cancer, starting at the age of 20 years [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H131800665"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients with KEB can have a normal life expectancy, but it can be reduced in cases of malignancies. Complications such as limited mobility of fingers, esophageal and urethral stenoses, conjunctivitis, and severe periodontitis are frequent and require ongoing care. The prognosis is usually poor for patients who develop mucocutaneous squamous cell carcinomas. Close clinical surveillance for early detection of mucocutaneous malignancies is therefore of key importance for these patients.</p><p>We examine patients with KEB once a year to adjust skin care and detect complications. A closer follow-up is indicated for patients treated for a mucocutaneous squamous cell carcinoma. The frequency of examinations may vary for the individual patient, based upon the extent of disease and the clinician's assessment of the risk for recurrence. (See  <a class="medical medical_review" href="/d/html/13713.html" rel="external">"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/3379.html" rel="external">"Posttreatment surveillance of squamous cell carcinoma of the head and neck"</a>.)</p><p class="headingAnchor" id="H3930438145"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/131341.html" rel="external">"Society guideline links: Epidermolysis bullosa"</a>.)</p><p class="headingAnchor" id="H131800677"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Kindler epidermolysis bullosa (KEB) is a rare autosomal recessive type of epidermolysis bullosa characterized by skin blistering, photosensitivity, progressive poikiloderma, sclerotic features, and squamous cell carcinomas of skin and mucosal membranes. KEB is caused by a broad spectrum of pathogenic variants in the <em>FERMT1</em> gene, encoding kindlin-1, an epithelial-specific protein expressed in the skin, periodontal tissues, and colon. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Skin blistering is usually present at birth with acral distribution  (<a class="graphic graphic_picture graphicRef103491" href="/d/graphic/103491.html" rel="external">picture 1</a>) and tends to decrease with age. Skin atrophy beginning on the dorsal aspects of the hands and feet  (<a class="graphic graphic_picture graphicRef103492" href="/d/graphic/103492.html" rel="external">picture 2</a>) starts in infancy or early childhood. In adults, the main cutaneous findings are poikiloderma  (<a class="graphic graphic_picture graphicRef103494" href="/d/graphic/103494.html" rel="external">picture 3</a>) and mucocutaneous scarring, leading to stenoses of the esophagus and genitourinary tract, ectropion, and webbing of fingers. (See <a class="local">'Clinical manifestations and natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The evaluation of a skin biopsy of a freshly induced blister by immunofluorescence microscopy or transmission electron microscopy is the first step in the diagnosis of KEB. The diagnosis is confirmed by the demonstration of variants in the <em>FERMT1</em> gene. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no specific treatment for KEB. The management is largely supportive and involves an interdisciplinary team for the treatment of the complications that occur progressively, such as limited mobility of fingers, esophageal and urethral stenoses, conjunctivitis, and severe periodontitis. All patients should adopt strict photoprotection measures and undergo regular skin examination for early detection of skin cancer starting in early adulthood. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 2014; 70:1103.</a></li><li><a class="nounderline abstract_t">Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020; 183:614.</a></li><li><a class="nounderline abstract_t">Chacón-Solano E, León C, Díaz F, et al. Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses. Br J Dermatol 2019; 181:512.</a></li><li class="breakAll">Youssefian L, Vahidnezhad H, Uitto J. Kindler syndrome. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Penagos H, Jaen M, Sancho MT, et al. Kindler syndrome in native Americans from Panama: report of 26 cases. Arch Dermatol 2004; 140:939.</a></li><li><a class="nounderline abstract_t">Youssefian L, Vahidnezhad H, Barzegar M, et al. The Kindler syndrome: a spectrum of FERMT1 mutations in Iranian families. J Invest Dermatol 2015; 135:1447.</a></li><li><a class="nounderline abstract_t">Jobard F, Bouadjar B, Caux F, et al. Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum Mol Genet 2003; 12:925.</a></li><li><a class="nounderline abstract_t">Siegel DH, Ashton GH, Penagos HG, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet 2003; 73:174.</a></li><li><a class="nounderline abstract_t">Zhan J, Yang M, Zhang J, et al. Kindler syndrome protein Kindlin-1 is mainly expressed in adult tissues originating from ectoderm/endoderm. Sci China Life Sci 2015; 58:432.</a></li><li><a class="nounderline abstract_t">Petricca G, Leppilampi M, Jiang G, et al. Localization and potential function of kindlin-1 in periodontal tissues. Eur J Oral Sci 2009; 117:518.</a></li><li><a class="nounderline abstract_t">Herz C, Aumailley M, Schulte C, et al. Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. J Biol Chem 2006; 281:36082.</a></li><li><a class="nounderline abstract_t">Kern JS, Herz C, Haan E, et al. Chronic colitis due to an epithelial barrier defect: the role of kindlin-1 isoforms. J Pathol 2007; 213:462.</a></li><li><a class="nounderline abstract_t">Karaköse E, Schiller HB, Fässler R. The kindlins at a glance. J Cell Sci 2010; 123:2353.</a></li><li><a class="nounderline abstract_t">Margadant C, Kreft M, Zambruno G, Sonnenberg A. Kindlin-1 regulates integrin dynamics and adhesion turnover. PLoS One 2013; 8:e65341.</a></li><li><a class="nounderline abstract_t">Patel H, Stavrou I, Shrestha RL, et al. Kindlin1 regulates microtubule function to ensure normal mitosis. J Mol Cell Biol 2016; 8:338.</a></li><li><a class="nounderline abstract_t">Qu H, Wen T, Pesch M, Aumailley M. Partial loss of epithelial phenotype in kindlin-1-deficient keratinocytes. Am J Pathol 2012; 180:1581.</a></li><li><a class="nounderline abstract_t">Shen C, Sun L, Zhu N, Qi F. Kindlin-1 contributes to EGF-induced re-epithelialization in skin wound healing. Int J Mol Med 2017; 39:949.</a></li><li><a class="nounderline abstract_t">Michael M, Begum R, Chan GK, et al. Kindlin-1 Regulates Epidermal Growth Factor Receptor Signaling. J Invest Dermatol 2019; 139:369.</a></li><li><a class="nounderline abstract_t">Patel H, Zich J, Serrels B, et al. Kindlin-1 regulates mitotic spindle formation by interacting with integrins and Plk-1. Nat Commun 2013; 4:2056.</a></li><li><a class="nounderline abstract_t">Rognoni E, Widmaier M, Jakobson M, et al. Kindlin-1 controls Wnt and TGF-β availability to regulate cutaneous stem cell proliferation. Nat Med 2014; 20:350.</a></li><li><a class="nounderline abstract_t">Zhang X, Luo S, Wu J, et al. KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage. J Invest Dermatol 2017; 137:475.</a></li><li><a class="nounderline abstract_t">Maier K, He Y, Wölfle U, et al. UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. Hum Mol Genet 2016; 25:5339.</a></li><li><a class="nounderline abstract_t">Maier K, He Y, Esser PR, et al. Single Amino Acid Deletion in Kindlin-1 Results in Partial Protein Degradation Which Can Be Rescued by Chaperone Treatment. J Invest Dermatol 2016; 136:920.</a></li><li><a class="nounderline abstract_t">Emmert H, Patel H, Brunton VG. Kindlin-1 protects cells from oxidative damage through activation of ERK signalling. Free Radic Biol Med 2017; 108:896.</a></li><li><a class="nounderline abstract_t">Heinemann A, He Y, Zimina E, et al. Induction of phenotype modifying cytokines by FERMT1 mutations. Hum Mutat 2011; 32:397.</a></li><li><a class="nounderline abstract_t">Techanukul T, Sethuraman G, Zlotogorski A, et al. Novel and recurrent FERMT1 gene mutations in Kindler syndrome. Acta Derm Venereol 2011; 91:267.</a></li><li><a class="nounderline abstract_t">Has C, Ludwig RJ, Herz C, et al. C-terminally truncated kindlin-1 leads to abnormal adhesion and migration of keratinocytes. Br J Dermatol 2008; 159:1192.</a></li><li><a class="nounderline abstract_t">Has C, Chmel N, Levati L, et al. FERMT1 promoter mutations in patients with Kindler syndrome. Clin Genet 2015; 88:248.</a></li><li><a class="nounderline abstract_t">Chmel N, Danescu S, Gruler A, et al. A Deep-Intronic FERMT1 Mutation Causes Kindler Syndrome: An Explanation for Genetically Unsolved Cases. J Invest Dermatol 2015; 135:2876.</a></li><li><a class="nounderline abstract_t">Fuchs-Telem D, Nousbeck J, Singer A, et al. New intragenic and promoter region deletion mutations in FERMT1 underscore genetic homogeneity in Kindler syndrome. Clin Exp Dermatol 2014; 39:361.</a></li><li><a class="nounderline abstract_t">Krishna CV, Parmar NV, Has C. Kindler syndrome with severe mucosal involvement in childhood. Clin Exp Dermatol 2014; 39:340.</a></li><li><a class="nounderline abstract_t">El Hachem M, Diociaiuti A, Proto V, et al. Kindler syndrome with severe mucosal involvement in a large Palestinian pedigree. Eur J Dermatol 2015; 25:14.</a></li><li><a class="nounderline abstract_t">Wiebe CB, Petricca G, Häkkinen L, et al. Kindler syndrome and periodontal disease: review of the literature and a 12-year follow-up case. J Periodontol 2008; 79:961.</a></li><li><a class="nounderline abstract_t">Wiebe CB, Penagos H, Luong N, et al. Clinical and microbiologic study of periodontitis associated with Kindler syndrome. J Periodontol 2003; 74:25.</a></li><li><a class="nounderline abstract_t">Has C, Castiglia D, del Rio M, et al. Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum Mutat 2011; 32:1204.</a></li><li><a class="nounderline abstract_t">Shimizu S, Nishie W, Tsuchiya K, et al. Kindler syndrome with severe intestinal involvement: a 31-year follow-up. Acta Derm Venereol 2014; 94:351.</a></li><li><a class="nounderline abstract_t">Mansur AT, Elcioglu NH, Aydingöz IE, et al. Novel and recurrent KIND1 mutations in two patients with Kindler syndrome and severe mucosal involvement. Acta Derm Venereol 2007; 87:563.</a></li><li><a class="nounderline abstract_t">Ezzine Sebaï N, Trojjet S, Khaled A, et al. [Kindler syndrome: three cases reports in three siblings]. Ann Dermatol Venereol 2007; 134:774.</a></li><li><a class="nounderline abstract_t">Hayashi S, Shimoya K, Itami S, Murata Y. Pregnancy and delivery with Kindler syndrome. Gynecol Obstet Invest 2007; 64:72.</a></li><li><a class="nounderline abstract_t">Lelli GJ Jr. Kindler syndrome causing severe cicatricial ectropion. Ophthal Plast Reconstr Surg 2010; 26:368.</a></li><li><a class="nounderline abstract_t">Guerrero-Aspizua S, Conti CJ, Escamez MJ, et al. Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. Orphanet J Rare Dis 2019; 14:183.</a></li><li><a class="nounderline abstract_t">Arita K, Wessagowit V, Inamadar AC, et al. Unusual molecular findings in Kindler syndrome. Br J Dermatol 2007; 157:1252.</a></li><li><a class="nounderline abstract_t">Lai-Cheong JE, Moss C, Parsons M, et al. Revertant mosaicism in Kindler syndrome. J Invest Dermatol 2012; 132:730.</a></li><li><a class="nounderline abstract_t">Kiritsi D, He Y, Pasmooij AM, et al. Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination. J Clin Invest 2012; 122:1742.</a></li><li><a class="nounderline abstract_t">Pasmooij AM, Jonkman MF, Uitto J. Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy. Discov Med 2012; 14:167.</a></li><li><a class="nounderline abstract_t">Has C, Liu L, Bolling MC, et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol 2020; 182:574.</a></li><li><a class="nounderline abstract_t">Hintner H, Stingl G, Schuler G, et al. Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases. J Invest Dermatol 1981; 76:113.</a></li><li><a class="nounderline abstract_t">Pohla-Gubo G, Cepeda-Valdes R, Hintner H. Immunofluorescence mapping for the diagnosis of epidermolysis bullosa. Dermatol Clin 2010; 28:201.</a></li><li><a class="nounderline abstract_t">Has C, He Y. Research Techniques Made Simple: Immunofluorescence Antigen Mapping in Epidermolysis Bullosa. J Invest Dermatol 2016; 136:e65.</a></li><li><a class="nounderline abstract_t">Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatol Clin 2010; 28:119.</a></li><li><a class="nounderline abstract_t">Has C, Kiritsi D, Mellerio JE, et al. The missense mutation p.R1303Q in type XVII collagen underlies junctional epidermolysis bullosa resembling Kindler syndrome. J Invest Dermatol 2014; 134:845.</a></li><li><a class="nounderline abstract_t">Larizza L, Roversi G, Volpi L. Rothmund-Thomson syndrome. Orphanet J Rare Dis 2010; 5:2.</a></li><li><a class="nounderline abstract_t">Koparir A, Gezdirici A, Koparir E, et al. Poikiloderma with neutropenia: genotype-ethnic origin correlation, expanding phenotype and literature review. Am J Med Genet A 2014; 164A:2535.</a></li><li><a class="nounderline abstract_t">Van Hove JL, Jaeken J, Proesmans M, et al. Clericuzio type poikiloderma with neutropenia is distinct from Rothmund-Thomson syndrome. Am J Med Genet A 2005; 132A:152.</a></li><li><a class="nounderline abstract_t">Arnold AW, Itin PH, Pigors M, et al. Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic criteria. Br J Dermatol 2010; 163:866.</a></li><li><a class="nounderline abstract_t">Mostefai R, Morice-Picard F, Boralevi F, et al. Poikiloderma with neutropenia, Clericuzio type, in a family from Morocco. Am J Med Genet A 2008; 146A:2762.</a></li><li><a class="nounderline abstract_t">Volpi L, Roversi G, Colombo EA, et al. Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. Am J Hum Genet 2010; 86:72.</a></li><li><a class="nounderline abstract_t">Has C, Burger B, Volz A, et al. Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer. Dermatology 2010; 221:309.</a></li><li><a class="nounderline abstract_t">El Hachem M, Zambruno G, Bourdon-Lanoy E, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis 2014; 9:76.</a></li><li><a class="nounderline abstract_t">Krämer SM, Serrano MC, Zillmann G, et al. Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines. Int J Paediatr Dent 2012; 22 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Figueira EC, Murrell DF, Coroneo MT. Ophthalmic involvement in inherited epidermolysis bullosa. Dermatol Clin 2010; 28:143.</a></li><li><a class="nounderline abstract_t">Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol 2016; 174:56.</a></li></ol></div><div id="topicVersionRevision">Topic 15510 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24690439" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32017015" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693469" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693469" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313809" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kindler syndrome in native Americans from Panama: report of 26 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599393" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Kindler syndrome: a spectrum of FERMT1 mutations in Iranian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668616" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12789646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25591451" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Kindler syndrome protein Kindlin-1 is mainly expressed in adult tissues originating from ectoderm/endoderm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19758247" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Localization and potential function of kindlin-1 in periodontal tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012746" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17955455" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic colitis due to an epithelial barrier defect: the role of kindlin-1 isoforms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592181" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The kindlins at a glance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776470" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Kindlin-1 regulates integrin dynamics and adhesion turnover.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26993041" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Kindlin1 regulates microtubule function to ensure normal mitosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22326752" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Partial loss of epithelial phenotype in kindlin-1-deficient keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28290610" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Kindlin-1 contributes to EGF-induced re-epithelialization in skin wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30248333" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Kindlin-1 Regulates Epidermal Growth Factor Receptor Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804033" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Kindlin-1 regulates mitotic spindle formation by interacting with integrins and Plk-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24681597" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Kindlin-1 controls Wnt and TGF-βavailability to regulate cutaneous stem cell proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27725201" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : UV-B-induced cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26827766" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single Amino Acid Deletion in Kindlin-1 Results in Partial Protein Degradation Which Can Be Rescued by Chaperone Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501563" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Kindlin-1 protects cells from oxidative damage through activation of ERK signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21309038" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Induction of phenotype modifying cytokines by FERMT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21336475" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Novel and recurrent FERMT1 gene mutations in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18652585" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : C-terminally truncated kindlin-1 leads to abnormal adhesion and migration of keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156791" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : FERMT1 promoter mutations in patients with Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A Deep-Intronic FERMT1 Mutation Causes Kindler Syndrome: An Explanation for Genetically Unsolved Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635080" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : New intragenic and promoter region deletion mutations in FERMT1 underscore genetic homogeneity in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635075" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Kindler syndrome with severe mucosal involvement in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25515598" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Kindler syndrome with severe mucosal involvement in a large Palestinian pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454678" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kindler syndrome and periodontal disease: review of the literature and a 12-year follow-up case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12593592" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical and microbiologic study of periodontitis associated with Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21936020" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kindler syndrome: extension of FERMT1 mutational spectrum and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002169" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Kindler syndrome with severe intestinal involvement: a 31-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989907" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel and recurrent KIND1 mutations in two patients with Kindler syndrome and severe mucosal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978719" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [Kindler syndrome: three cases reports in three siblings].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284921" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy and delivery with Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592640" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Kindler syndrome causing severe cicatricial ectropion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31340837" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854379" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Unusual molecular findings in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089829" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Revertant mosaicism in Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466645" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021371" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31090061" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6161971" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20447482" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immunofluorescence mapping for the diagnosis of epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27342035" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Research Techniques Made Simple: Immunofluorescence Antigen Mapping in Epidermolysis Bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945624" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005051" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The missense mutation p.R1303Q in type XVII collagen underlies junctional epidermolysis bullosa resembling Kindler syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113479" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Rothmund-Thomson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25044170" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Poikiloderma with neutropenia: genotype-ethnic origin correlation, expanding phenotype and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15558713" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clericuzio type poikiloderma with neutropenia is distinct from Rothmund-Thomson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618321" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18925663" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Poikiloderma with neutropenia, Clericuzio type, in a family from Morocco.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004881" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938162" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mild clinical phenotype of Kindler syndrome associated with late diagnosis and skin cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884811" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937908" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oral health care for patients with epidermolysis bullosa--best clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945628" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ophthalmic involvement in inherited epidermolysis bullosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302137" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
